“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

Pulling the Pfizer EUA would remove the only COVID-19 vaccine approved for all children from the US market. The Moderna ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda, sending its ...

Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

The Novavax COVID-19 vaccine that could soon win federal approval may offer a boost for the U.S. military: an opportunity to get shots into some of the thousands of service members who have ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

The company announced the vaccine's efficacy was 91% in "high-risk" populations. Novavax researchers also took a close look at sequencing data for 54 of the 77 Covid-19 cases in the study.

Novavax COVID vaccine shows strong efficacy The biotechnology company announced Monday that its stage three clinical trial showed overall efficacy of 90.4% against COVID-19.